Atricure, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atricure, Inc. on April 12, 2006, covering events that occurred on April 6, 2006. The filing details corporate governance changes, specifically regarding director compensation and board appointments.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on non-financial corporate actions.
Material Changes
- Director Compensation Increase: The Board approved immediate changes to non-employee director compensation. The annual retainer was set at $20,000. Additional fees were established for committee chairs: $25,000 for the Board Chairman, $10,000 for the Audit Committee Chair, and $5,000 each for the Compensation and Nominating/Corporate Governance Committee Chairs.
- Stock Option Grants: Initial stock option grants for new directors increased from 20,000 to 50,000 shares. Annual grants for existing directors (serving at least six months) increased from 3,000 to 10,000 shares. A retroactive grant of 30,000 shares was approved for directors standing for re-election.
- Meeting Fees: Fees for Board meetings are $1,500 (in-person) and $500 (telephone). Committee meeting fees are $750 (in-person) and $350 (telephone).
- Board Appointment: Gene R. McGrevin was appointed to the Board of Directors and the Compensation Committee on April 6, 2006.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, risk factors, or discussion of contingencies. It is a procedural report regarding board composition and compensation policy.
Key Facts for Investor Verification
- Verify the total number of non-employee directors to assess the aggregate impact of the increased compensation and stock option grants on the company's expense structure.
- Confirm the vesting schedules for the new 50,000-share initial grants and the 30,000-share retroactive grants to understand future dilution.
- Review the press release filed as Exhibit 99.1 for additional context on Gene R. McGrevin's background and qualifications.